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Digoxin and Platelet Activation in Patients With Atrial Fibrillation:
In Vivo and In Vitro Study
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Background-—Digoxin use was shown to be associated with an increased risk of cardiovascular events in atrial fibrillation (AF). We
hypothesized that digoxin may affect cardiovascular risk by increasing platelet activation.
Methods and Results-—Post hoc analysis of a prospective study of anticoagulated patients with AF. Patients were divided into
2 groups balanced for age, sex, and cardiovascular risk factors: digoxin users (n=132) and nonusers (n=388). Urinary excretion of
11-dehydro-thromboxane B2 (TxB2), a marker of platelet activation, and serum digoxin concentration (SDC) were measured. In vitro
experiments were performed on platelets from healthy subjects and AF patients, which were incubated with scalar doses of digoxin
(0.6–2.4 ng/mL) with or without prestimulation with a sub-threshold of collagen. Median 11-dehydro-TxB2 was 105.0 (interquartile
range, 60.0–190.0) ng/mg creatinine, and median SDC was 0.65 (interquartile range, 0.40–1.00) ng/mL. Urinary 11-dehydro-TxB2
and SDC were correlated (rs=0.350, P<0.001). Patients in the upper tertile of SDC showed higher 11-dehydro-TxB2 compared with
non–digoxin users (P=0.019). In vitro study showed an increased basal platelet activation in patients with AF compared with
healthy subjects. Digoxin (2.4 ng/mL) induced calcium mobilization, PAC-1 (procaspase-activating compound 1) and platelet
aggregation in AF patients but not in healthy subjects. After pretreatment with a sub-threshold of collagen, digoxin dose-dependent
induced calcium mobilization, arachidonic acid release, TxB2 biosynthesis, PAC-1 and soluble platelet selectin expression, and
platelet aggregation, which were inhibited by antibody against digoxin.
Conclusions-—We found a significant in vivo correlation between SDC and platelet activation. Supratherapeutic SDC increased
in vitro platelet aggregation via calcium-related phospholipase A2 phosphorylation. Our findings may have clinical implications for
AF patients treated with digoxin. ( J Am Heart Assoc. 2018;7:e009509. DOI: 10.1161/JAHA.118.009509.)
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D igoxin is still widely used for acute and chronic heartrate control in patients with atrial fibrillation (AF),
particularly in those patients not achieving a good heart rate
or who are unable to tolerate therapy with b-blockers, or
when heart failure coexists.1
Recent studies raised concerns on the use of digoxin in AF
because of a putative increased risk of cardiovascular and all-
cause mortality in patients given digoxin.2,3 However, current
evidence on this issue is still controversial,4 given the lack of
a randomized trial specifically aimed at testing digoxin safety
in AF. Furthermore, the biologic mechanism underlying such
association is still elusive.
Two previous studies performed in patients with
heart failure investigated the relationship between serum
digoxin concentration (SDC) and cardiac adverse events,
showing that SDC above the therapeutic range (ie,
>1.2 ng/mL) was associated with an increased risk of
ventricular arrhythmias and mortality.5,6 It is also
noteworthy that in the DIG (Digitalis Investigation Group)
trial, SDC in the range of 0.5 to 0.7 ng/mL was associated
with the lowest risk of all-cause mortality, while higher SDC
(1.6–2.0 ng/mL) was associated with increased
mortality.7
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Digoxin acts by inhibiting the sodium-potassium ATPase
pump on the membrane of cardiac myocytes, causing an
increase in sodium and intracellular calcium, resulting in
increased myocardial contractility. Similarly, digoxin binds a
specific sodium-potassium ouabain-like receptor present on
the platelet surface.8 In vitro studies demonstrated that
ouabain, a glycoside with analogous characteristics as
digoxin, increases platelet reactivity to other agonists such
as thrombin by increasing calcium mobilization.9,10 Also,
digoxin was demonstrated to increase platelet calcium
mobilization8 and expression of platelet-binding receptors
such as P-selectin,11 but direct evidence of the effect of
digoxin on platelet activation is still lacking.
These effects may be particularly relevant in patients with
AF in whom digoxin use could exacerbate platelet activation,
which is associated with an increased cardiovascular disease
incidence.12
We hypothesized that the association between digoxin use
and cardiovascular disease may be dependent on digoxin’s
ability to activate platelets. To test this hypothesis (1) we
investigated in vivo the relationship between platelet activa-
tion and SDC in a population of patients with nonvalvular AF
treated or not with digoxin; and (2) we performed an in vitro
study incubating platelets with scalar doses of digoxin to
explore the possible interplay between digoxin and platelet
aggregation and the underlying mechanism.
Materials and Methods
The data, analytic methods, and study materials will not be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure.
In Vivo Study
This is a post hoc analysis from an observational prospective
cohort study including 815 patients with AF, 171 of whom
were treated with digoxin.13 Of these, 14 patients were
excluded, as they were taking aspirin in addition to vitamin K
antagonists, and 25 patients did not have a urine sample (not
mandatory for the study). Thus, the study group included 132
patients with AF taking digoxin. To compare urinary 11-
dehydro- thromboxane B2 (TxB2) excretion, we included a
group of 388 patients with AF not treated with digoxin and
balanced for cardiovascular risk factors, as shown in Table 1.
Inclusion and exclusion criteria have been previously
described.13 For all patients, baseline medications were
collected, including type and dose of each drug taken by
patients.
The study protocol was approved by the Sapienza Univer-
sity Institutional Review Board and was conducted in accor-
dance to the declaration of Helsinki. Patients gave informed
consent to participate in the study. The study was registered
at ClinicalTrials.gov (NCT01882114).
Laboratory Analysis
After overnight fasting, blood samples obtained from patients
with AF and healthy subjects (HS) after supine rest for at least
10 minutes, were taken into tubes with 3.8% sodium citrate
and centrifuged at 300g for 10 minutes to obtain supernatant
and immediately stored at 80°C until use. All products,
when not differently specified, are from Sigma Aldrich.
Serum Digoxin Concentration
SDC was measured on the AxSYM analyzer (Abbott Labora-
tories, Abbott Park, IL) using the Digoxin III Reagent pack (Ref.
Table 1. Baseline Characteristics of Patients With AF Taking
or Not Taking Digoxin Balanced for Risk Factors
Digoxin Users
(n=132)
Non–Digoxin
Users (n=388) P Value
Age, y 75.27.2 74.67.8 0.480
Women, % 47.7 46.9 0.920
Hypertension, % 92.4 87.4 0.152
Diabetes mellitus, % 25.0 19.8 0.219
Heart failure, % 29.5 22.4 0.101
History of stroke/TIA, % 18.2 14.7 0.334
History of MI, % 22.7 19.3 0.451
11-dehydro-TxB2
(ng/mg creatinine)
101.0
[60.0–174.5]
110.0
[60.0–183.75]
0.602*
AF indicates atrial fibrillation; MI, myocardial infarction; TIA, transient ischemic attack;
TxB2, Thromboxane B2.
*Mann-Whitney test.
Clinical Perspective
What Is New?
• Serum digoxin is associated with increased urinary excre-
tion of thromboxane B2 in patients with atrial fibrillation, and
in vitro experiments showed that digoxin increased platelet
function in prestimulated platelets.
What Are the Clinical Implications?
• Patients should be kept in the therapeutic range of digoxin
to avoid not only proarrhythmic side effects related to
digoxin but also an increase in platelet activation that may
lead to thrombotic complications.
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6L07, rev. September 2010, Abbott, Wiesbaden, Germany).
The sensitivity of the AxSYM Digoxin II assay was calculated
to be 0.3 ng/mL.
In Vitro Study
To evaluate platelet activation we analyzed [Ca2+]i mobiliza-
tion, which is the “primum movens” of platelet activation, and
expression of PAC-1 (procaspase-activating compound 1),
which is an antibody that recognizes an epitome of the
glycoprotein IIb/IIIa of activated platelets, at/or near the
platelet fibrinogen receptor. Finally, we measured platelet
aggregation, which is part of the sequence of events leading
to thrombus formation. The above reported markers of
platelet activation were studied in platelets isolated from
patients with AF (n=3, 2 men and 1 woman) and HS (n=5, 3
men and 2 women). Then, to study the pathway involved in
digoxin-mediated platelet activation, we studied platelets from
HS to avoid confounding factors from concomitant drugs
potentially influencing platelet function such as those taken
by patients with AF. Hence, to mimic the platelet preactivation
found in patients with AF, we treated platelets from HS with
subthreshold concentrations of collagen, as previously
reported by Nocella et al.14
Platelet Aggregation
Venous blood was drawn in trisodium citrate (3.8%, 1/10 [v:
v]) from healthy subjects (n=5) and patients with AF not
treated with digoxin (n=3) who had fasted for at least
12 hours. To obtain platelet-rich plasma (PRP), blood was
centrifuged for 15 minutes at 180g at room temperature, and
the supernatant PRP was separated.15 To avoid leukocyte
contamination, only the top 75% of the PRP was collected.
PRP samples were treated with digoxin (0.6–2.4 ng/mL),
ouabain (4 lmol/L) and/or pretreated with a subthreshold
concentration (STC) of collagen (Mascia Brunelli, 0.25 lg/
mL) as a primer. STC concentration of agonists was defined as
the highest concentration that elicited <20% platelet aggre-
gation. Based on a previous work showing an increased
cardiovascular risk at 1.2 ng/mL,6 we used 3 SDCs, 1 within
the therapeutic range (0.6 ng/mL), 1 threshold value
(1.2 ng/mL), and 1 above the therapeutic range (2.4 ng/mL).
To evaluate the specific pathways of digoxin-mediated
platelet activation, samples were treated with the antibody
antidigoxin (4 lmol/L), or the phospholipase A2 (PLA2)
inhibitor arachidonyl trifluoromethyl ketone (AACOCF3)
(14 lmol/L) or the calcium chelator ethylenediaminete-
traacetic acid (EDTA) (2 mmol/L) (20 minute at 37°C before
activation).
Platelet aggregation was performed on a Bio/Data
8-channel platelet aggregometer (PAP-8E BioData) using
siliconized glass cuvettes under continuous stirring at 180 g,
using techniques based on the method of Born.16 After
stimulation with agonists, samples were centrifuged for
3 minutes at 300 g. Supernatants were stored at 80°C for
analysis of 11-dehydro-TxB2 and pellets were stored at 80°C
for analysis of cytosolic PLA2 (cPLA2) phosphorylation and
arachidonic acid production.
Western Blot Analysis of cPLA2 Protein
Phosphorylation
Platelet pellets were suspended in a 2X Lysis buffer (5 mmol/L
EDTA, 0.15 mol NaCl, 0.1 mol Tris pH 8.0, 1% triton, and
10 lg/mL of protease and phosphatase inhibitors cocktail).
The protein concentration of each lysate was determined by
Bradford assay. Equal amounts of protein (30 lg/lane) were
solubilized in a 2X Leammli sample buffer containing 20% of
2-mercaptoethanol and were electrophoretically separated on
a 10% SDS-polyacrylamide gel and then electro-transferred to
nitrocellulose membranes. After blocking with bovine serum
albumin 5% (Sigma Aldrich, Saint Louis, MO), the membranes
were incubated overnight at 4°C with polyclonal anti-p-cPLA2
antibody, raised against an amino acid sequence recognizing
the phosphorylation in the Ser505 site of cPLA2, or polyclonal
anti-cPLA2 antibody antibodies, and as loading control mouse
monoclonal anti-b-actin antibody (Santa Cruz Biotechnology,
Dallas, TX). Subsequently, the membranes were incubated with
secondary antibody (Santa Cruz Biotechnology; 1:5000), and
then the immune complexes were detected by enhanced
chemiluminescence substrate. Densitometric analysis of the
bands was performed using Image J software, and signal
density was normalized to b-actin density.
Platelet and Urinary Thromboxane
Platelet TxA2 generation was analyzed as previously
described14 by evaluating its stable metabolite TxB2 by ELISA
commercial kit (Cusabio Technology, Houston, TX) and
expressed as pg/mL9108 cells.
The excretion of the stable urinary metabolite 11-dehydro-
TxB2 was measured by an enzyme-linked immunosorbent
assay commercial kit (Cusabio Technology). Data are
expressed as pg/mg creatinine. Intra- and interassay coeffi-
cients of variation were 4.0% and 3.6%, respectively.
Measurement of [Ca2+]i Mobilization
Platelet [Ca2+]i mobilization was measured in PRP incubated
for 20 minutes at 37°C with 8 lmol/L FLUO 4-acetoxymethyl
ester (FLUO 4-AM; Invitrogen, Waltham, MA) in dimethyl
sulfoxide. One milliliter of Tyrode buffer was added, and the
mixture was analyzed by the Epics XL-MCL Cytometer
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(Coulter Electronics, Hialeah, FL) equipped with an argon laser
at 488 nm. The basal fluorescence intensity corresponding to
FLUO 4-AM was measured for 1 minute in the platelet
population identified in the gate as CD61-positive events.
Digoxin (0.6–2.4 ng/mL), ouabain (4 lmol/L) or an STC of
agonists alone or digoxin 2.4 ng/mL in presence of an STC of
agonists with antidigoxin, EDTA, or AACOCF3 were added and
data acquired for 1 minute.
Platelet Arachidonic Acid Assay
Arachidonic acid (AA) was analyzed in platelets by gas
chromatography as previously described.17,18 Briefly, AA was
processed for direct transesterification with acetyl chloride,
which allowed for the derivatization of both free and esterified
fatty acid as methyl ester. These samples were added with
methyl heptadecanoate as internal standard and identifica-
tion, precision, and accuracy were evaluated using mixtures of
authentic methylated fatty acid standards and a control
plasma pool as previously described.19 Analyses were
performed on an Agilent 7820A Plus Gas Chromatograph
(Agilent Technologies, Santa Clara, CA) equipped with a
G4513A automatic liquid sampler and a flame-ionization
detector (GC-FID). Separation was carried out on a 100-m
capillary column (Supelco, SP-2560 100 m 3 0.25 mm inner
diameter, 0.20 mm thickness; Sigma Aldrich, Milan, Italy).
Flow Cytometry Analysis of PAC-1
Platelet suspension (200 lL, 29108/mL) was incubated for
30 minutes at 37°C with or without digoxin (0.6–2.4 ng/mL),
ouabain (4 lmol/L) or STC of agonists alone or digoxin
2.4 ng/mL in the presence of an STC of agonists with
antidigoxin, EDTA, or AACOCF3. Platelets were then fixed with
(2%) paraformaldehyde (0.1% bovine serum albumin) for
60 minutes at room temperature. The suspension was treated
with monoclonal antibody (20 lL) for 60 minutes at 4°C. The
unbound monoclonal antibody was removed by centrifugation
at 300g for 3 minutes (twice) after the addition of phosphate-
buffered saline (0.1% bovine serum albumin). Fluorescence
intensity was analyzed on BD FACSCanto Flow Cytometer
(Coulter Electronics) equipped with an argon laser at
857 mm. For every histogram, 50 000 platelets were counted
to evaluate the percentage of positive platelets. Antibody
reactivity was reported as mean fluorescence intensity.
sP-Selectin Assay
In the supernatant of above reported experiments we evaluated
sP-selectin levels by a commercial immunoassay (DRG Inter-
national, Springfield, NJ) and values were expressed as ng/mL.
Intra- and interassay coefficients of variation were <10%.
Statistical Analysis
Categorical variables were reported as counts and percent-
ages. Continuous variables were expressed as mean SD or
as median and interquartile range or median and minimum-
maximum values. We tested the independence of categorical
variables by v2 test. Student t test was used to compare
means and Mann-Whitney U test to compare medians.
The Spearman rank-order correlation test (rs) was used to
perform correlation analysis.
Groups comparison was performed by the Kruskal-Wallis
test.
Only P values lower than 0.05 were considered statistically
significant. All tests were 2-tailed, and analyses were
performed using computer software packages (SPSS-22.0,
IBM, Armonk, NY).
Results
In Vivo Study
Clinical characteristics of patients with AF according to
digoxin treatment are reported in Table 1. Mean age of
patients on digoxin was 75.27.2 years, and 47.7% were
women. The 2 groups were balanced for the main cardiovas-
cular risk factors (Table 1).
Median SDC was 0.65 ng/mL (interquartile range, 0.40–
1.00, min-max 0.30–2.45 ng/mL), whereas median urinary
11-dehydro-TxB2 was 105.0 (interquartile range, 60.0–190.0)
ng/mg creatinine. A significant correlation was found
between SDC and urinary 11-dehydro-TxB2 (rs=0.350,
P<0.001). In particular, when we divided SDC into tertiles,
we found that patients in the highest tertile of SDC,
corresponding to a median value of 1.17 ng/mL, had
significantly higher 11-dehydro-TxB2 levels compared with
those in the first tertile (Table 2; P<0.001).
Of note, patients in the first 2 tertiles of SDC showed
similar 11-dehydro-TxB2 levels compared with patients not
treated with digoxin, while patients in the third tertile had
significantly higher 11-dehydro-TxB2 levels compared with
digoxin nonusers (P=0.019).
Vivo Study
Digoxin and platelet activation in HS and AF patients
Basal levels of [Ca2+]i mobilization, PAC-1 expression, and
platelet aggregation were higher in AF patients compared with
HS (Figure 1A through 1C). After incubation of platelets with
digoxin (2.4 ng/mL), we found a significant increase in [Ca2+]i
mobilization, PAC-1 expression, and platelet aggregation
compared with unstimulated platelets only in platelets from
patients with AF, whereas digoxin alone did not affect platelet
activation in samples from HS (Figure 1A through 1C). No
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effect was seen with 0.6 to 1.2 ng/mL of digoxin (data not
shown).
In Vitro Study on Healthy Subjects
Patients with AF usually have cardiovascular comorbidities
and take several different drugs that can potentially affect
platelet function, and present with a basal increased platelet
activation compared with HS, we performed in vitro experi-
ments in platelets from HS (n=5, males 3, females 2, age
33.84.1 years) pretreated with an STC of collagen
(0.25 lg/mL) in order to mimic the preactivation found in
platelets from AF.
As no effect was seen with 0.6 to 1.2 ng/mL of digoxin
(data not shown), in each in vitro experiment we reported only
the effect of 2.4 ng/mL (first column).
[Ca2+]i Mobilization
[Ca2+]i mobilization is a fundamental step for platelet activa-
tion.20 Compared with STC alone, digoxin up to 2.4 ng/mL or
ouabain significantly increased [Ca2+]i mobilization (Figure 2A).
Treatment with antidigoxin and with EDTA significantly inhib-
ited [Ca2+]i mobilization (Figure 2A). Digoxin alone did not
induce any change in [Ca2+]i mobilization (Figure 2A).
PAC-1 Expression
PAC-1 is an antibody that recognizes an epitome of the
glycoprotein IIb/IIIa of activated platelets at/or near the
platelet fibrinogen receptor.
While digoxin alone had no effects on IIb/IIIa expression,
incubation of platelets stimulated with an STC of collagen
(0.25 lg/mL) with scalar concentrations of digoxin (0.6–
2.4 ng/mL) induced a dose-dependent increase of sP-selectin
compared with STC alone (Figure 2B); similar findings were
observed with ouabain as positive control.
Conversely, pretreatment of platelets with the antibody
against digoxin or AACOCCF3, a specific PLA2 inhibitor and/
Table 2. Levels of Urinary 11-Dehydro-TxB2 According to
Tertiles of SDC
Digoxin
Tertiles
SDC (ng/mL)
(Median, IQR)
11-Dehydro-TxB2
(ng/mg Creatinine)
(Median, IQR)
P Value for
11-Dehydro-
TxB2
First tertile 0.29 [0.20–0.40] 76.0 [50.0–130.0] Ref.
Second tertile 0.60 [0.58–0.74] 100.0 [61.25–150.0] 0.213
Third tertile 1.17 [1.00–1.50] 148.5 [87.5–200.0] <0.001
IQR indicates interquartile range; SDC, serum digoxin concentration; TxB2, thromboxane
B2.
Kruskal–Wallis Test for 11-dehydro-TxB2: P<0.001.
Figure 1. Comparison of in vivo digoxin-induced platelet
activation in HS and patients with AF. A, [Ca2+]i mobiliza-
tion in platelets incubated with or without digoxin alone
(2.4 ng/mL) in patients with AF (n=3) or HS (n=5)
(*P<0.001). B, glycoprotein IIb/IIIa expression (PAC-1) in
platelets incubated with or without digoxin (2.4 ng/mL) in
patients with AF (n=3) or HS (n=5) (*P<0.001). C, Platelet
aggregation in platelet-rich plasma incubated with or
without digoxin (2.4 ng/mL) in patients with AF (n=3) or
HS (n=5) (*P<0.001). AF indicates atrial fibrillation; HS,
healthy subjects; PAC-1, procaspase-activating compound
1.
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Figure 2. In vitro digoxin-induced platelet activation in HS. A, [Ca2+]i mobilization in platelets incubated with digoxin alone (2.4 ng/mL) or
prestimulated with an STC of collagen (0.25 lg/mL) and activated with scalar concentrations of digoxin (0.6–2.4 ng/mL) or ouabain in the
presence or not of antibody against digoxin or EDTA (*P<0.05, **P<0.001, n=3 experiments). B, IIb/IIIb expression (PAC-1) in platelets
incubated with scalar concentrations of digoxin (0.6–2.4 ng/mL) or ouabain and prestimulated with an STC of collagen (0.25 lg/mL) in the
presence or not of antibody against digoxin, EDTA, or AACOCF3 (n=3 experiments) (*P<0.05, **P<0.001). C, Platelet aggregation in platelet-rich
plasma incubated with digoxin alone (2.4 ng/mL) or prestimulated with an STC of collagen (0.25 lg/mL) and activated with scalar
concentrations of digoxin (0.6–2.4 ng/mL) or ouabain and in the presence or not of antibody against digoxin, EDTA, or AACOCF3 (n=5
experiments) (*P<0.05, **P<0.001). D, Representative tracing of platelet aggregation. AACOCF3 indicates arachidonyl trifluoromethyl ketone;
EDTA, ethylenediaminetetraacetic acid; HS, healthy subjects; PAC-1, procaspase-activating compound 1; STC, subthreshold concentration.
DOI: 10.1161/JAHA.118.009509 Journal of the American Heart Association 6
Digoxin and Platelet Activation Pastori et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on March 4, 2019
or EDTA, a calcium chelator, significantly inhibited digoxin-
induced IIb/IIIa expression (Figure 2B).
Platelet Aggregation
While digoxin alone had no effect on platelet aggregation,
incubation of platelets with an STC stimulated with scalar
concentrations of digoxin (0.6–2.4 ng/mL) induced a dose-
dependent increase of platelet aggregation compared with
STC alone (Figure 2C and 2D); similar findings were observed
with ouabain as positive control. Increase of platelet aggre-
gation was already observed with 0.6 ng/mL digoxin but
reached significance with 1.2 ng/mL (Figure 2C and 2D).
Conversely, pretreatment of platelets with antidigoxin or
AACOCCF3, a specific PLA2 inhibitor, and/or EDTA, a calcium
chelator, significantly inhibited digoxin-induced platelet aggre-
gation (Figure 2C and 2D).
TxB2 biosynthesis, granule release (sP-selectin), cPLA2
phosphorylation, and AA
To further study the potential mechanism of platelet activa-
tion, we evaluated TxB2; granule release, as assessed by
sP-selectin; PLA2 phosphorylation, a key enzyme for the
release of eicosanoids from the platelet membrane21; and AA
production.
Digoxin alone had no effect on TxB2 biosynthesis, P-
selectin release, PLA2 phosphorylation, and AA increase,
while incubation of platelets stimulated with an STC of
collagen (0.25 lg/mL) and scalar concentrations of digoxin
(0.6–2.4 ng/mL) showed a dose-dependent increase of TxB2
production, P-selectin release, PLA2 phosphorylation, and AA
release compared with STC alone (Figure 3A through 3E).
Similar results were observed by treating platelets with
ouabain (Figure 3A through 3E). Pretreatment of
platelets with antidigoxin or AACOCF3 or EDTA, significantly
inhibited digoxin-induced platelet activation (Figure 3A
through 3E).
Discussion
In this study, we showed a direct correlation between serum
digoxin and urinary excretion of 11-dehydro-TxB2, a marker
reflecting platelet activation and cyclooxygenase activity in
patients with AF. We also demonstrated in vitro that digoxin
induces platelet aggregation via calcium-related PLA2 phos-
phorylation and TxB2 biosynthesis.
The data presented here are in keeping with an earlier
study comparing 16 patients with AF taking digoxin (mean
digoxin level=0.93 ng/dL) with 14 patients not taking
digoxin.11 The first group had significantly increased levels
of a marker of platelet activation such as P-selectin. However,
it was unclear if platelet changes were related to digoxin
concentration and the mechanism potentially accounting for
such association was not investigated.
In our study, we found a significant correlation between
SDC and urinary excretion of 11-dehydro-TxB2, suggesting an
interplay between digoxin levels and platelet activation. Of
note, in this regard, patients in the first 2 tertiles of SDC (ie,
<1 ng/mL), showed a similar degree of platelet activation
compared with patients not receiving digoxin. Conversely,
those in the upper tertile of SDC disclosed a significantly
higher excretion of 11-dehydro-TxB2 compared with non–
digoxin users.
Based on this, we performed an in vitro study experiment
using the circulating concentration of digoxin detected
in digoxin-treated patients experiencing cardiovascular
disease.7
We found that digoxin significantly increased platelet
aggregation and TxB2 biosynthesis in platelets from patients
with AF. Hence, incubation of digoxin alone (without pretreat-
ment of platelet with a subthreshold of agonist) activated
platelets from patients with AF but not from HS, suggesting
that digoxin may act as “second hit” in enhancing platelet
function in conditions where a basal increased platelet
activation is already present. Thus, platelets from patients
with AF present a certain degree of basal activation
attributable to the concomitant presence of multiple cardio-
vascular comorbidities, such as hypertension and diabetes
mellitus, which are known to be associated with increased
platelet activation.22,23 This result is in keeping with a
previous work showing no difference in ex vivo and in vitro
platelet activation in 20 HS randomized to receive digoxin or
placebo for 10 days.24
To explore a potential underlying mechanism, we focused
on calcium mobilization, which is crucial for AA metabolism
and TxB2 biosynthesis.
20 We found that digoxin induced
platelet calcium mobilization in a dose-dependent fashion,
which was inhibited by treatment with a specific antibody
against digoxin.
Then, we investigated the calcium-mediated PLA2 phos-
phorylation, which represents the step forward leading to
TxB2 production, and glycoprotein IIb/IIIa activation via AA
release.21 We found that digoxin specifically induced platelet
PLA2 phosphorylation, resulting in AA mobilization and TxB2
biosynthesis. This effect was digoxin-related as confirmed by
the similar results obtained with the digoxin-like compound
ouabain. Furthermore, the pretreatment of samples with a
specific antibody against digoxin completely suppressed
platelet activation. Moreover, the specific inhibitor of PLA2,
namely, AACOCF3, almost completely inhibited digoxin-
induced platelet activation and TxB2 biosynthesis, reinforcing
the hypothesis that digoxin-induced platelet activation was
dependent on calcium mobilization and eventually PLA2
activation.
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Our study has clinical implications. We found that SDCs
exceeding the therapeutic range (ie, >1.2 ng/mL), favor in vitro
activation only in primed platelets, indicating the need of
substimulated platelets to obtain extensive aggregation. This
finding reinforces the importance of keeping patients in the
therapeutic range of SDCs to avoid not only proarrhythmic side
Figure 3. Mechanisms of digoxin-induced platelet activation. A, 11-dehydro-TxB2 production from platelets incubated with
scalar concentrations of digoxin (0.6–2.4 ng/mL) or ouabain and prestimulated with an STC of collagen (0.25 lg/mL) in the
presence or not of antibody against digoxin, EDTA, or AACOCF3 (n=5 experiments in healthy subjects) (*P<0.05, **P<0.001).
B, sP-selectin release in platelets incubated with scalar concentrations of digoxin (0.6–2.4 ng/mL) or ouabain and prestimulated
with an STC f collagen (0.25 lg/mL) in the presence or not of antibody against digoxin, EDTA, or AACOCF3 (n=3 experiments)
(*P<0.05, **P<0.001). C, cPLA2 phosphorylation was analyzed in platelets incubated with digoxin alone (2.4 ng/mL) or
prestimulated with an STC of collagen (0.25 lg/mL) and activated with scalar concentrations of digoxin (0.6–2.4 ng/mL) or
ouabain in the presence or not of antibody against digoxin, EDTA, or AACOCF3 (*P<0.05, **P<0.001; n=3 experiments in
healthy subjects). D, Arachidonic acid production in platelets incubated with digoxin alone (2.4 ng/mL) or prestimulated with an
STC of collagen (0.25 lg/mL) and activated with scalar concentrations of digoxin (0.6–2.4 ng/mL) or ouabain in the presence
or not of antibody against digoxin EDTA or AACOCF3 (*P<0.05, **P<0.001; n=3 experiments in healthy subjects).
E, Representative western blot of cPLA2 phosphorylation. AACOCF3 indicates arachidonyl trifluoromethyl ketone; Ab, antibody;
cPLA2, cytosolic phospholipase A2; EDTA, ethylenediaminetetraacetic acid; STC, subthreshold concentration; TxB2, thromboxane
B2
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effects related to digoxin but also an increase in platelet
activation that may lead to thrombotic complications. Indeed,
our findings provide novel insight into the increased risk of
cardiovascular disease observed in AF with an SDC >1.2 ng/
mL.
This study presents limitations that need to be mentioned.
Despite the fact that we found a significant correlation
between SDC and urinary TxB2, we cannot exclude that other
pathways may be involved in the digoxin-related platelet
activation. Moreover, we included only Caucasian patients with
AF, and, in addition, the relationship between digoxin and
platelet function may be different in other cardiovascular
settings, such as in patients with heart failure in sinus rhythm.
In conclusion, we found a significant correlation between
digoxin and platelet activation in vivo in patients with AF treated
with vitamin K antagonists. Digoxin induced in vitro platelet
TxB2 formation via calcium mobilization, PLA2 phosphorylation,
and eventually AA release. Monitoring digoxin concentration
and platelet activation may be relevant to reduce the cardio-
vascular risk in patients with AF.
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